B. Riley Securities Reiterates Buy on Cue Biopharma, Lowers Price Target to $25
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Mayank Mamtani reiterates Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $83 to $25.
B. Riley Securities analyst Mayank Mamtani reiterates Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $83 to $25.
